Literature DB >> 29215625

Response to Reinink.

Konstantinos Papamichael1, Adam S Cheifetz1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29215625     DOI： 10.1038/ajg.2017.375

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  8 in total

1.  Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.

Authors:  Namita Singh; Casey J Rosenthal; Gil Y Melmed; James Mirocha; Sharmayne Farrior; Silvia Callejas; Bhavna Tripuraneni; Shervin Rabizadeh; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2014-10       Impact factor: 5.325

Review 2.  Therapeutic Drug Monitoring in IBD: Prospective Promise Unfulfilled.

Authors:  Shail M Govani; Akbar K Waljee
Journal:  Am J Gastroenterol       Date:  2017-03-21       Impact factor: 10.864

Review 3.  Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy.

Authors:  Konstantinos Papamichael; Adam S Cheifetz
Journal:  Am J Gastroenterol       Date:  2017-02-21       Impact factor: 10.864

4.  Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.

Authors:  Konstantinos Papamichael; Filip Baert; Sophie Tops; Gert Van Assche; Paul Rutgeerts; Severine Vermeire; Ann Gils; Marc Ferrante
Journal:  J Crohns Colitis       Date:  2016-07-11       Impact factor: 9.071

5.  A Pharmacokinetic Rationale for Proactive Therapeutic Drug Monitoring of Anti-TNF Drugs.

Authors:  Andrew R Reinink
Journal:  Am J Gastroenterol       Date:  2017-12       Impact factor: 10.864

6.  Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.

Authors:  Konstantinos Papamichael; Karen A Chachu; Ravy K Vajravelu; Byron P Vaughn; Josephine Ni; Mark T Osterman; Adam S Cheifetz
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-30       Impact factor: 11.382

7.  Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.

Authors:  Konstantinos Papamichael; Thomas Van Stappen; Niels Vande Casteele; Ann Gils; Thomas Billiet; Sophie Tops; Karolien Claes; Gert Van Assche; Paul Rutgeerts; Severine Vermeire; Marc Ferrante
Journal:  Clin Gastroenterol Hepatol       Date:  2015-12-08       Impact factor: 11.382

8.  Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study.

Authors:  Byron P Vaughn; Manuel Martinez-Vazquez; Vilas R Patwardhan; Alan C Moss; William J Sandborn; Adam S Cheifetz
Journal:  Inflamm Bowel Dis       Date:  2014-11       Impact factor: 5.325
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.